Therefore, it is quite reasonable to speculate that during lenvatinib treatment, previously administered anti-PD-1/PD-L1 antibody treatment exerts an effect on immune cells as well as tumor cells and induces a synergistic effect with lenvatinib, similar to that observed in the combination therapy of MTAs with ICIs. This evidence concerns the gene PDCD1 and neoplasm.